Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration

Table 6 Timeline of lymphatic filariasis programme activities in American Samoa, 1999–2011

Year	Activity	Survey population size	Age group	Prevalence (% antigenemia, ICT)	MDA coverage (% total population treated)
1999	Nationwide mapping (convenience survey) [3]	3018 (18 villages)	All	16.5
2000	MDA [9]				19
2001	MDA [9]				51
2001	Sentinel survey [10]	1024 (4 villages)	All	11.52
2002	MDA [9]				49
2003	Drug distributor evaluation Community KAP survey Programme modifications [9]
2003	MDA [9]				71
2003	Drug distributor evaluation Church leader survey Programme modifications [9]
2003	Sentinel survey [10]	917 (4 villages)	All	13.74
2004	MDA [9]				65
2004	Drug coverage survey [9]				86
2005	MDA [9]				67
2006	MDA [9]				70
2006	Sentinel survey [10]	1371 (4 villages)	All	0.95
2006	Purposeful survey [11]	569 (3 villages)	>5 years	4.22
2007	Random household C-survey (spatial sampling design)	1881 (national)	All	2.29
2010	Random household survey (spatial sampling design) [15]	807 (national)	≥18 years	3.2 (Og4C3 antigen ELISA)
2011	TAS [18]	949	6–7 years	0.21

ELISA enzyme-linked immunosorbent assay, ICT immunochromatographic card test, KAP knowledge, attitudes, practices, MDA mass drug administration, TAS transmission assessment survey

ISSN: 1349-4147